.. Facteurs-influencés-par-l-'imc, . %mg, and .. Obésité-et-inflammation-biologique, 21 a. Composition corporelle et type de rhumatisme inflammatoire, IMC, %MG, obésité et traitements adjuvants, vol.21, issue.22, p.23

B. Glintborg, B. Østergaard, M. Krogh, N. Dreyer, L. Kristensen et al., Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry, Annals of the Rheumatic Diseases, vol.69, issue.11, pp.2002-2010, 2010.
DOI : 10.1136/ard.2009.124446

M. Hetland, I. Christensen, U. Tarp, L. Dreyer, A. Hansen et al., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis & Rheumatism, vol.64, issue.5, pp.22-32, 2010.
DOI : 10.7326/0003-4819-148-2-200801150-00192

J. Braun, J. Brandt, J. Listing, A. Zink, R. Alten et al., Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis, Annals of the Rheumatic Diseases, vol.64, issue.2, 2005.
DOI : 10.1136/ard.2004.025130

S. Arends, E. Brouwer, E. Van-der-veer, H. Groen, M. Leijsma et al., Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study, Arthritis Research & Therapy, vol.13, issue.3, p.94, 2011.
DOI : 10.1136/ard.2008.089979

A. Edrees, S. Misra, and N. Abdou, Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions, Clin Exp Rheumatol, vol.23, issue.4, pp.469-74, 2005.

T. Takeuchi, N. Miyasaka, Y. Tatsuki, T. Yano, T. Yoshinari et al., Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.70, issue.7, pp.1208-1223, 2011.
DOI : 10.1136/ard.2011.153023

K. Hyrich, K. Watson, A. Silman, D. Symmons, T. Bsr-biologics et al., Predictors of response to anti-TNF-?? therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, Rheumatology, vol.45, issue.12, pp.1558-65, 2006.
DOI : 10.1093/rheumatology/kel149

S. Au, M. Ramirez-fort, and A. Gottlieb, Analysis of Trial Data for Infliximab and Golimumab: Baseline C-Reactive Protein Level and Prediction of Therapeutic Response in Patients With Psoriatic Arthritis, Arthritis Care & Research, vol.40, issue.7, pp.1114-1122
DOI : 10.1016/j.semarthrit.2010.07.004

S. Vermeire, G. Van-assche, and P. Rutgeerts, C-Reactive Protein as a Marker for Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.10, issue.5, pp.661-666, 2004.
DOI : 10.1097/00054725-200409000-00026

S. Arends, E. Van-der-veer, C. Kallenberg, E. Brouwer, and A. Spoorenberg, Baseline predictors of response to TNF-?? blocking therapy in ankylosing spondylitis, Current Opinion in Rheumatology, vol.24, issue.3, 2012.
DOI : 10.1097/BOR.0b013e32835257c5

D. Mulleman, F. Lauféron, D. Wendling, D. Ternant, E. Ducourau et al., Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study, Arthritis Research & Therapy, vol.13, issue.3, p.82, 2011.
DOI : 10.1136/ard.2004.030452

URL : https://hal.archives-ouvertes.fr/hal-00922332

D. Ternant, D. Mulleman, F. Lauféron, C. Vignault, E. Ducourau et al., Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis, British Journal of Clinical Pharmacology, vol.33, issue.4, pp.55-65
DOI : 10.1007/s10928-006-9012-6

R. Landewé, Conventional DMARDs in axial spondyloarthritis: wishful??rather than rational?thinking! Ann Rheum Dis, pp.951-954, 2015.

M. Heiberg, W. Koldingsnes, K. Mikkelsen, E. Rødevand, C. Kaufmann et al., The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study, Arthritis Rheum Feb, vol.1559, issue.2, pp.234-274, 2008.

. St, E. Clair, C. Wagner, A. Fasanmade, B. Wang et al., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum, vol.46, issue.6, pp.1451-1460, 2002.

C. Dannepond, A. Maruani, L. Machet, D. Ternant, G. Paintaud et al., Serum Infliximab Concentrations in Psoriatic Patients Treated with Infliximab: A Systematic Review, Acta Dermato Venereologica, vol.95, issue.4, pp.401-407
DOI : 10.2340/00015555-1980

URL : https://hal.archives-ouvertes.fr/hal-01190167

H. Takahashi, H. Tsuji, A. Ishida-yamamoto, and H. Iizuka, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, The Journal of Dermatology, vol.15, issue.1, 2013.
DOI : 10.1002/ibd.20899

K. Bendtzen, P. Geborek, M. Svenson, L. Larsson, M. Kapetanovic et al., Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor ?? inhibitor infliximab, Arthritis & Rheumatism, vol.45, issue.12, pp.3782-3791, 2006.
DOI : 10.1002/art.22214

E. Ducourau, D. Mulleman, G. Paintaud, M. Lin, D. Lauféron et al., Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases, Arthritis Research & Therapy, vol.13, issue.3, p.105, 2011.
DOI : 10.3109/03009740903177745

URL : https://hal.archives-ouvertes.fr/hal-00922822

C. Plasencia, D. Pascual-salcedo, S. García-carazo, L. Lojo, L. Nuño et al., The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients, Arthritis Research & Therapy, vol.15, issue.4, p.79, 2013.
DOI : 10.1136/ard.2009.124446

D. Ternant, E. Ducourau, A. Perdriger, A. Corondan, L. Goff et al., Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis, British Journal of Clinical Pharmacology, vol.79, issue.1, pp.118-146
DOI : 10.1016/j.jbspin.2011.11.004

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168386

S. Mori, A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy, Modern Rheumatology, vol.73, issue.2, pp.83-91, 2007.
DOI : 10.1016/j.jbspin.2006.01.007

Z. Xu, K. Seitz, A. Fasanmade, J. Ford, P. Williamson et al., Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis, The Journal of Clinical Pharmacology, vol.26, issue.suppl 28, pp.681-95, 2008.
DOI : 10.1592/phco.26.6.813

R. Maini, F. Breedveld, J. Kalden, J. Smolen, D. Davis et al., Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis, Arthritis & Rheumatism, vol.6, issue.9, pp.1552-63, 1998.
DOI : 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

T. Schaeverbeke, M. Truchetet, M. Kostine, T. Barnetche, B. Bannwarth et al., Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice, Rheumatology, vol.55, issue.2, pp.210-230
DOI : 10.1093/rheumatology/kev277

E. Maser, R. Villela, M. Silverberg, and G. Greenberg, Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn???s Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.10, pp.1248-54, 2006.
DOI : 10.1016/j.cgh.2006.06.025

G. Wolbink, Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.64, issue.5, pp.704-711, 2005.
DOI : 10.1136/ard.2004.030452

E. Gremese, A. Carletto, M. Padovan, F. Atzeni, B. Raffeiner et al., Obesity and reduction of the response rate to anti-tumor necrosis factor ?? in rheumatoid arthritis: An approach to a personalized medicine, Arthritis Care & Research, vol.70, issue.Suppl, pp.94-100, 2013.
DOI : 10.1136/ard.2010.135376

M. Sandberg, C. Bengtsson, H. Källberg, A. Wesley, L. Klareskog et al., Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.72, issue.(1), pp.2029-2062, 2014.
DOI : 10.1136/annrheumdis-2012-202254

R. Klaasen, C. Wijbrandts, D. Gerlag, and P. Tak, Body mass index and clinical response to infliximab in rheumatoid arthritis, Arthritis & Rheumatism, vol.54, issue.Suppl 3, pp.359-64, 2011.
DOI : 10.1002/art.21671

E. Gremese, S. Bernardi, S. Bonazza, M. Nowik, G. Peluso et al., Body weight, gender and response to TNF-?? blockers in axial spondyloarthritis, Rheumatology, vol.53, issue.5, pp.875-81, 2014.
DOI : 10.1093/rheumatology/ket433

URL : http://doi.org/10.1093/rheumatology/ket433

S. Ottaviani, Y. Allanore, F. Tubach, M. Forien, A. Gardette et al., Body mass index influences the response to infliximab in ankylosing spondylitis, Arthritis Research & Therapy, vol.14, issue.3, p.115, 2012.
DOI : 10.1093/bja/aeq195

URL : https://hal.archives-ouvertes.fr/inserm-00704843

F. Maas, S. Arends, E. Van-der-veer, F. Wink, M. Efde et al., Obesity Is Common in Axial Spondyloarthritis and Is Associated with Poor Clinical Outcome, The Journal of Rheumatology, vol.43, issue.2, 2016.
DOI : 10.3899/jrheum.150648

D. Minno, M. Peluso, R. Iervolino, S. Lupoli, R. Russolillo et al., Obesity and the prediction of minimal disease activity: A prospective study in psoriatic arthritis, Arthritis Care & Research, vol.295, issue.Suppl 2, pp.141-148, 2013.
DOI : 10.1001/jama.295.19.2275

P. Højgaard, B. Glintborg, L. Kristensen, B. Gudbjornsson, T. Love et al., The influence of obesity on response to tumour necrosis factor-?? inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries, Rheumatology, vol.55, issue.12, pp.2191-2200, 2016.
DOI : 10.1093/rheumatology/kew326

J. Harper, M. Sinanan, and T. Zisman, Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.19, issue.10, pp.2118-2142, 2013.
DOI : 10.1097/MIB.0b013e31829cf401

V. Rocha and P. Libby, Obesity, inflammation, and atherosclerosis, Nature Reviews Cardiology, vol.107, issue.6, 2009.
DOI : 10.1161/01.CIR.103.16.2096

S. Weisberg, D. Mccann, M. Desai, M. Rosenbaum, R. Leibel et al., Obesity is associated with macrophage accumulation in adipose tissue, Journal of Clinical Investigation, vol.112, issue.12, pp.1796-808, 2003.
DOI : 10.1172/JCI19246DS1

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC296995

M. Bahceci, D. Gokalp, S. Bahceci, A. Tuzcu, S. Atmaca et al., The correlation between adiposity and adiponectin, tumor necrosis factor ??, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?, Journal of Endocrinological Investigation, vol.43, issue.3, pp.210-214, 2007.
DOI : 10.1016/j.jacc.2003.11.039

G. Hotamisligil, P. Arner, J. Caro, R. Atkinson, and B. Spiegelman, Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance., Journal of Clinical Investigation, vol.95, issue.5, pp.2409-2424, 1995.
DOI : 10.1172/JCI117936

A. Bond, R. Asher, R. Jackson, K. Sager, K. Martin et al., Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels, European Journal of Gastroenterology & Hepatology, vol.28, issue.3, pp.271-277, 2016.
DOI : 10.1097/MEG.0000000000000544

J. Rosas, F. Llinares-tello, J. Senabre-gallego, X. Barber-vallés, G. Santos-soler et al., Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis, Clin Exp Rheumatol. Feb, vol.35, issue.1, pp.145-153, 2017.

A. Romero-corral, V. Somers, J. Sierra-johnson, Y. Korenfeld, S. Boarin et al., Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality, European Heart Journal, vol.31, issue.6, pp.737-783, 2010.
DOI : 10.1093/eurheartj/ehp487

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838679

F. Abbasi, B. Jr, B. Lamendola, C. Mclaughlin, T. Reaven et al., Relationship between obesity, insulin resistance, and coronary heart disease risk, Journal of the American College of Cardiology, vol.40, issue.5, pp.937-980, 2002.
DOI : 10.1016/S0735-1097(02)02051-X

URL : http://doi.org/10.1016/s0735-1097(02)02051-x

D. Okorodudu, M. Jumean, V. Montori, A. Romero-corral, V. Somers et al., Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis, International Journal of Obesity, vol.85, issue.5, pp.791-800, 2010.
DOI : 10.1016/S0140-6736(07)61778-4

A. Romero-corral, V. Somers, J. Sierra-johnson, R. Thomas, M. Collazo-clavell et al., Accuracy of body mass index in diagnosing obesity in the adult general population, International Journal of Obesity, vol.9, issue.6, pp.959-66, 2008.
DOI : 10.1067/mhj.2001.119420

R. Wellens, A. Roche, H. Khamis, A. Jackson, M. Pollock et al., Relationships Between the Body Mass Index and Body Composition, Obesity Research, vol.60, issue.6, pp.35-44, 1996.
DOI : 10.1080/07315724.1992.10718272

M. George and J. Baker, The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care, Current Rheumatology Reports, vol.25, issue.3, p.6, 2016.
DOI : 10.1097/EDE.0000000000000075

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809046

G. Summers, C. Deighton, M. Rennie, and A. Booth, Rheumatoid cachexia: a clinical perspective, Rheumatology, vol.47, issue.8, pp.1124-1155, 2008.
DOI : 10.1093/rheumatology/ken146

URL : http://doi.org/10.1093/rheumatology/ken146

S. Elder, S. Roberts, M. Mccrory, S. Das, P. Fuss et al., Effect of Body Composition Methodology on Heritability Estimation of Body Fatness, The Open Nutrition Journal, vol.6, issue.1, pp.48-58, 2012.
DOI : 10.2174/1874288201206010048

R. Fleischmann, D. Van-der-heijde, A. Koenig, R. Pedersen, A. Szumski et al., How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?, Annals of the Rheumatic Diseases, vol.37, issue.(Suppl 11), pp.1132-1139, 2015.
DOI : 10.3899/jrheum.091333

J. Zochling, Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS) Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score Arthritis Care Res, Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S), pp.47-58, 2011.

S. Snitker, Use of Body Fatness Cutoff Points, Mayo Clinic Proceedings, vol.85, issue.11, p.1057, 2010.
DOI : 10.4065/mcp.2010.0583

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2966372

C. Lavie, R. Milani, H. Ventura, D. Schutter, A. Romero-corral et al., Use of Body Fatness Cutoff Points???Reply???I, Mayo Clinic Proceedings, vol.85, issue.11, pp.1057-1065, 2010.
DOI : 10.4065/mcp.2010.0624

L. Ho-pham, L. Campbell, and T. Nguyen, More on Body Fat Cutoff Points, Mayo Clinic Proceedings, vol.86, issue.6, 2011.
DOI : 10.4065/mcp.2011.0097

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104919

A. Oreopoulos, C. Lavie, S. Snitker, and A. Romero-corral, More on Body Fat Cutoff Points???Reply???I, Mayo Clinic Proceedings, vol.86, issue.6
DOI : 10.4065/mcp.2011.0156

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104920

U. Kyle, Y. Schutz, Y. Dupertuis, and C. Pichard, Body composition interpretation, Nutrition, vol.19, issue.7-8, pp.7-8597, 2003.
DOI : 10.1016/S0899-9007(03)00061-3

Y. Schutz, U. Kyle, and C. Pichard, Fat-free mass index and fat mass index percentiles in Caucasians aged 18-98, Int J Obes Relat Metab Disord, vol.26, issue.7, pp.953-60, 2002.

D. Vries, M. Wolbink, G. Stapel, S. De-vrieze, H. Van-denderen et al., Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation, Annals of the Rheumatic Diseases, vol.66, issue.9, pp.1252-1256, 2007.
DOI : 10.1136/ard.2007.072397

U. Klotz, A. Teml, and M. Schwab, Clinical Pharmacokinetics and Use??of??Infliximab, Clinical Pharmacokinetics, vol.20, issue.1, pp.645-60, 2007.
DOI : 10.3748/wjg.v11.i8.1187

T. Witte, Methotrexate as combination partner of TNF inhibitors and tocilizumab. What is reasonable from an immunological viewpoint?, Clinical Rheumatology, vol.84, issue.Suppl 10, pp.629-663, 2015.
DOI : 10.1016/j.yexmp.2008.03.003

C. Plasencia, D. Pascual-salcedo, L. Nuño, G. Bonilla, A. Villalba et al., Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab, Annals of the Rheumatic Diseases, vol.71, issue.12, pp.1955-60, 2012.
DOI : 10.1136/annrheumdis-2011-200828

D. Ternant, A. Aubourg, C. Magdelaine-beuzelin, D. Degenne, H. Watier et al., Infliximab Pharmacokinetics in Inflammatory Bowel Disease Patients, Therapeutic Drug Monitoring, vol.PAP, 2008.
DOI : 10.1097/FTD.0b013e318180e300

URL : https://hal.archives-ouvertes.fr/hal-00616549

A. Ogdie and P. Weiss, The Epidemiology Psoriatic Arthritis. Rheum Dis Clin North Am, pp.545-68, 2015.

A. Gardette, S. Ottaviani, J. Sellam, F. Berenbaum, F. Lioté et al., Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study, Clinical Rheumatology, vol.5, issue.12, 2016.
DOI : 10.1371/journal.pone.0014328

Y. Pers, M. Godfrin-valnet, J. Lambert, C. Fortunet, E. Constant et al., Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient, J Rheumatol. 2015, vol.42, issue.4, pp.580-584

A. Gardette, S. Ottaviani, J. Sellam, F. Berenbaum, F. Lioté et al., Body mass index and response to abatacept in rheumatoid arthritis, European Journal of Clinical Investigation, vol.14, issue.Suppl 2, pp.1048-52, 2016.
DOI : 10.1186/ar3900

F. Iannone, D. Courvoisier, J. Gottenberg, M. Hernandez, E. Lie et al., Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the ???pan-European registry collaboration for abatacept (PANABA), Clinical Rheumatology, vol.73, issue.S3, 2016.
DOI : 10.1136/annrheumdis-2013-204573

X. Mariette, R. Alten, H. Nüßlein, M. Galeazzi, H. Lorenz et al., The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study, Joint Bone Spine, 2016.
DOI : 10.1016/j.jbspin.2016.10.011

D. Pascual-salcedo, C. Plasencia, R. S. Nuño, L. Bonilla, G. Nagore et al., Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis, Rheumatology, vol.50, issue.8, pp.1445-52, 2011.
DOI : 10.1093/rheumatology/ker124

T. Pradeu, S. Jaeger, and E. Vivier, The speed of change: towards a discontinuity theory of immunity?, Nature Reviews Immunology, vol.4, issue.10, pp.764-773, 2013.
DOI : 10.1126/scisignal.2001608

URL : https://hal.archives-ouvertes.fr/hal-01343694

L. Heimans, M. Van-den-broek, S. Le-cessie, B. Siegerink, N. Riyazi et al., Association of High Body Mass Index With Decreased Treatment Response to Combination Therapy in Recent-Onset Rheumatoid Arthritis Patients, Arthritis Care & Research, vol.13, issue.8, pp.1235-1277, 2013.
DOI : 10.1111/j.1467-789X.2011.00970.x

J. Lovejoy, C. Champagne, L. De-jonge, H. Xie, and S. Smith, Increased visceral fat and decreased energy expenditure during the menopausal transition, International Journal of Obesity, vol.6, issue.6, pp.949-58, 2005.
DOI : 10.2337/diacare.23.6.801

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748330

P. Deurenberg, J. Weststrate, and J. Seidell, Body mass index as a measure of body fatness: age- and sex-specific prediction formulas, British Journal of Nutrition, vol.46, issue.02, pp.105-119, 1991.
DOI : 10.1079/BJN19780152

P. Deurenberg, M. Yap, and W. Van-staveren, Body mass index and percent body fat: a meta analysis among different ethnic groups, International Journal of Obesity, vol.22, issue.12, 1998.
DOI : 10.1038/sj.ijo.0800741

P. Deurenberg, M. Deurenberg-yap, and S. Guricci, Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship, Obesity Reviews, vol.53, issue.3, pp.141-147, 2002.
DOI : 10.1038/sj.ijo.0801353

P. Schreiner, J. Terry, G. Evans, W. Hinson, J. Crouse et al., Sex-specific Associations of Magnetic Resonance Imaging-derived Intra-abdominal and Subcutaneous Fat Areas with Conventional Anthropometric Indices: The Atherosclerosis Risk in Communities Study, American Journal of Epidemiology, vol.144, issue.4, pp.335-380, 1996.
DOI : 10.1093/oxfordjournals.aje.a008934

B. Thorand, J. Baumert, A. Döring, C. Herder, H. Kolb et al., Sex differences in the relation of body composition to markers of inflammation, Atherosclerosis, vol.184, issue.1, 2006.
DOI : 10.1016/j.atherosclerosis.2005.04.011

J. Clasey, C. Bouchard, C. Teates, J. Riblett, M. Thorner et al., The Use of Anthropometric and Dual-Energy X-ray Absorptiometry (DXA) Measures to Estimate Total Abdominal and Abdominal Visceral Fat in Men and Women, Obesity Research, vol.45, issue.3, pp.256-64, 1999.
DOI : 10.2337/diab.45.5.633

M. Cushman, C. Legault, E. Barrett-connor, M. Stefanick, C. Kessler et al., Effect of Postmenopausal Hormones on Inflammation-Sensitive Proteins : The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study, Circulation, vol.100, issue.7, pp.717-739, 1999.
DOI : 10.1161/01.CIR.100.7.717

S. Lakoski and D. Herrington, Effects of hormone therapyon C-reactive protein and IL-6 in postmenopausal women: a review article, Climacteric, vol.85, issue.4, pp.317-343, 2005.
DOI : 10.1161/01.CIR.0000028463.74880.EA

A. Festa, D. Agostino, R. Williams, K. Karter, A. Mayer-davis et al., The relation of body fat mass and distribution to markers of chronic inflammation, International Journal of Obesity, vol.25, issue.10, pp.1407-1422, 2001.
DOI : 10.1038/sj.ijo.0801792

P. Barbe and P. Ritz, Composition corporelle. Cah Nutr Diététique, pp.172-178, 2005.
DOI : 10.1016/s0007-9960(05)80484-5

A. Coin, G. Sergi, N. Minicuci, S. Giannini, E. Barbiero et al., Fat-free mass and fat mass reference values by dual-energy X-ray absorptiometry (DEXA) in a 20???80 year-old Italian population, Clinical Nutrition, vol.27, issue.1, pp.87-94, 2008.
DOI : 10.1016/j.clnu.2007.10.008

M. And and M. , an observational-monocentric and cross-sectional study, we included consecutive patients treated by IFX for 2 months and more. We collected BMI and %BF from dual-energy X-ray absorptiometry. Serum samples were collected for assay of TSI and anti-IFX antibody (TSI)